PhD in Synthetic Medicinal Chemistry Targeting Blood Coagulation Factors XIa and XIIa
Explore the development of novel inhibitors targeting coagulation factors XIa and XIIa to create safer cardiovascular therapies. Combine advanced synthetic chemistry and biochemical evaluation in a cutting-edge research environment at University of Galway.
AI-generated overview
Project Description
Project Overview
This project focuses on discovering novel small-molecule inhibitors targeting intrinsic blood coagulation cascade components, specifically factors XIa and XIIa. Thrombosis is a leading cause of mortality via myocardial infarction and ischemic stroke, and current antithrombotic drugs pose bleeding risks. The aim is to create safer, selective antithrombotic agents through advanced synthetic and medicinal chemistry.
What You Will Do
The candidate will join the School of Biological and Chemical Sciences at the University of Galway, supervised by Dr. Dmitrii Kalinin. The research involves multistep organic synthesis combined with microscale parallel synthesis to generate diverse small molecule libraries. These will be evaluated with enzyme inhibition assays and blood coagulation functional tests, providing experience bridging synthetic chemistry, medicinal chemistry, and pharmacology.
Expected Outcomes
The research is expected to yield new therapeutic candidates with high selectivity and improved safety profiles for treatment of cardiovascular diseases. The project also offers valuable interdisciplinary skills in drug discovery applicable to both academic and industrial sectors.
Why This Matters
Thrombosis-related diseases cause significant global mortality. Developing safer antithrombotic agents can reduce bleeding complications associated with current therapies, improving patient outcomes and addressing urgent medical needs worldwide.
Entry Requirements
How to Apply
Eligibility
Supervisor Profile
Dr. Dmitrii Kalinin specializes in synthetic and medicinal chemistry with a focus on drug discovery, especially creating and evaluating small molecule therapeutic candidates. His research integrates organic synthesis with pharmacological analysis to address cardiovascular and other significant diseases. He is recognized for combining traditional and cutting-edge synthesis techniques to develop novel bioactive compounds.